Carl Ola Landgren, MD

Dr Gilberto Lopes is a medical oncologist and researcher who focuses on new anticancer drug development and global oncology. He has published more than 270 scientific papers and has led hundreds of clinical trials. Dr Lopes was the main investigator of Keynote 42, a clinical trial that demonstrated the efficacy of the immunotherapy drug pembrolizumab in people living with lung cancer. This groundbreaking study led to one of the FDA approvals of pembrolizumab. Additionally, Dr Lopes has contributed significantly to the development of several chemotherapies and targeted medications that address specific molecular changes in tumors.

Dr Kazandjian is a hematologic oncologist and clinician-scientist whose clinical research focuses on multiple myeloma and its precursor plasma cell dyscrasias (monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma). Dr Kazandjian has a particularly strong interest in identifying high-risk smoldering myeloma patients who may benefit from early treatment strategies and the development of early-interventional clinical trials targeting this patient population. In addition, his translational research interests lie in the development of modern and novel laboratory techniques, including next generation sequencing (NGS) to advance monitoring of minimal residual disease (MRD) and the immune cell repertoire during treatment.

Dr Angela Zhu is a board-certified ophthalmologist at the Bascom Palmer Eye Institute with a double fellowship specialization in both pediatric and adult cornea, cataract, and external diseases. She is focused on caring for patients of all ages with a variety of ocular surface and anterior segment disorders using cutting-edge medical and surgical techniques. After receiving her bachelor's degrees in Chemistry and Biology from the Massachusetts Institute of Technology, Dr Zhu spent a dedicated research year at the Whitehead Institute of Biomedical Research investigating mammalian immune responses to bacterial infections.